NEW YORK, and MONTREAL, Nov. 6 /CNW Telbec/ - Crystal Research
Associates, LLC announced today that it has issued an Executive Informational
Overview(R) (EIO(R)) on Haemacure Corporation (TSX: HAE). The full 48-page
report can be found at www.crystalra.com.
Haemacure Corporation is a Canadian specialty bio-therapeutics company
developing human, high-value therapeutic proteins and plasma protein-derived
biosurgical products based on its patented, high-yield fibrinogen and thrombin
extraction and purification technology. Haemacure's product pipeline includes
Hemaseel(R)HMN, a fibrin sealant to enter pivotal Phase II/Phase III clinical
trials, and Hemaseel(R)Thrombin, an hemostat in pre-clinical stage. Fibrin
sealants are biological products used during surgery to stop or control
bleeding, seal tissues, and speed wound healing. Fibrin sealants are also
believed to be effective drug delivery devices and adhesion prevention agents.
Hemostats help blood clot.
Haemacure recently announced that it was setting-up a manufacturing
facility in Sarasota, Florida, expected to be completed by mid-2008, without
requiring additional equity. The facility will produce fibrin sealant for the
pivotal Phase II/Phase III trials and for commercialization once the product
is approved by the U.S. FDA. The completion of the facility, as planned, will
also allow Haemacure to have the first patient undergo surgery in these
pivotal trials during the first quarter of 2009. Haemacure's fibrin sealant
demonstrated safety and efficacy in 151 subjects and patients in past clinical
Moreover, Haemacure has discovered in one of its two plasma fractions
four proteins for which the Company believes significant, expanding markets
exist, as well as seven enzymes that may have potential as Orphan Drugs. These
proteins and enzymes are at an early, investigational stage. Haemacure seeks
to develop these proteins and enzymes in collaboration with pharmaceutical and
biotechnology companies. Pending successful development, they may increase
Haemacure's revenues per liter of plasma. The Company estimates that its
revenues per liter could be several times above industry averages, due to the
high yield of its extraction technology. The Company also sells two
FDA-cleared fibrin sealant delivery devices-HemaSyst(TM) and HemaMyst(TM).
Well over $50 million has been invested to develop Haemacure's extraction
technology. The Company is headquartered in Montréal, Canada, and operates a
subsidiary in Sarasota, Florida.
About Crystal Research Associates, LLC
Crystal Research Associates, LLC is an independent research firm that
provides institutional-quality, fee-based research to small and mid-cap
companies. Crystal Research Associates' unique and novel product, the
Executive Informational Overview(R) (EIO(R)), is free of investment ratings,
target prices, and forward-looking financial models. The EIO(R) presents a
crystal clear, detailed report on a company (public or private) in a manner
that is easily understood by the Wall Street financial community. The EIO(R)
details a company's product/technology/service offerings, market size(s), key
intellectual property, leadership, growth strategy, competition, risks,
audited financial statements, key events, and other such fundamental
information. Crystal Research Associates has offices in New York City, Delray
Beach, Montréal, and Toronto. Crystal Research Associates has been compensated
by the Company in cash of thirty-five thousand U.S. dollars and two hundred
thousand options/warrants to purchase Haemacure stock for its services in
creating the base report, for updates, and for printing.
Forward-Looking Safe Harbor Statement
Statements in this news release regarding future financial and operating
results, potential applications of the Company's technology, opportunities for
the Company, and any other statements about the future expectations, beliefs,
goals, plans, or prospects expressed constitute forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995.
Any statements that are not statements of historical fact (including
statements containing the words "will," "believes," "plans," "anticipates,"
"expects," "estimates," and similar expressions) should also be considered to
be forward-looking statements. There are a number of important factors that
could cause actual results or events to differ materially from those indicated
by such forward-looking statements including: limited operating history, need
for future capital, and economic conditions generally. Additional information
on potential factors that could affect results and other risks and
uncertainties are detailed from time to time in the Company's periodic
reports, including forms filed with SEDAR.
These statements, and other forward-looking statements, are not
guarantees of future performance and involve risks and uncertainties. Crystal
Research Associates assumes no obligation to update any of the forward-looking
statements in this release.
For further information:
For further information: Crystal Research Associates, LLC: Jeffrey J.
Kraws, firstname.lastname@example.org; Karen B. Goldfarb, email@example.com, (609)
306-2274, F: (609) 395-9339; Corporation Haemacure: Joseph Galli, Chairman and
Chief Executive Officer, (514) 990-7074, firstname.lastname@example.org; Gilles Lemieux,
Secretary and Investor Relations, (514) 282-3350 ext. 22,